- Home
- HBNC vs MYGN Comparison
HBNC vs MYGN Comparison
Compare HBNC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- MYGN
- Stock Information
- Founded
- HBNC 1873
- MYGN 1991
- Country
- HBNC United States
- MYGN United States
- Employees
- HBNC N/A
- MYGN N/A
- Industry
- HBNC Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HBNC Finance
- MYGN Health Care
- Exchange
- HBNC Nasdaq
- MYGN Nasdaq
- Market Cap
- HBNC 708.6M
- MYGN 744.7M
- IPO Year
- HBNC N/A
- MYGN 1995
- Fundamental
- Price
- HBNC $15.88
- MYGN $4.51
- Analyst Decision
- HBNC Hold
- MYGN Hold
- Analyst Count
- HBNC 2
- MYGN 15
- Target Price
- HBNC $17.00
- MYGN $15.14
- AVG Volume (30 Days)
- HBNC 178.6K
- MYGN 1.3M
- Earning Date
- HBNC 07-23-2025
- MYGN 08-05-2025
- Dividend Yield
- HBNC 4.02%
- MYGN N/A
- EPS Growth
- HBNC 88.54
- MYGN N/A
- EPS
- HBNC 1.02
- MYGN N/A
- Revenue
- HBNC $201,164,000.00
- MYGN $831,300,000.00
- Revenue This Year
- HBNC $46.44
- MYGN N/A
- Revenue Next Year
- HBNC $4.83
- MYGN $6.68
- P/E Ratio
- HBNC $15.60
- MYGN N/A
- Revenue Growth
- HBNC 11.46
- MYGN 7.38
- 52 Week Low
- HBNC $12.70
- MYGN $3.81
- 52 Week High
- HBNC $19.18
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- HBNC 58.02
- MYGN 40.01
- Support Level
- HBNC $15.29
- MYGN $4.97
- Resistance Level
- HBNC $15.97
- MYGN $5.37
- Average True Range (ATR)
- HBNC 0.41
- MYGN 0.28
- MACD
- HBNC -0.02
- MYGN -0.07
- Stochastic Oscillator
- HBNC 58.40
- MYGN 2.34
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.